ÉúÎïͨ±¨µÀ À´×Ô¹ãÎ÷ʦ·¶´óѧ¡¢Ö¥¼Ó¸ç´óѧµÄÑо¿ÈËÔ±½Òʾ£¬Src/FAK½éµ¼µÄAFC7Á×Ëữ¶ÔÓÚACF7ÔÚÕ³ºÏ°ß´¦½áºÏF-action¼°Ð­µ÷µÄϸ°û¹Ç¼Ü¶¯Á¦Ñ§ÖÁ¹ØÖØÒª¡£ÕâÒ»Ñо¿·¢ÏÖ·¢²¼ÔÚ5ÔÂ24Èյġ¶×ÔȻͨѶ¡·£¨Nature Communications£©ÔÓÖ¾ÉÏ¡£

¹ãÎ÷ʦ·¶´óѧµÄÁººê£¨Hong Liang£©½ÌÊÚ¡¢Ñî·å£¨Feng Yang£©½ÌÊÚ£¬ÒÔ¼°Ö¥¼Ó¸ç´óѧµÄXiaoyang Wu²©Ê¿ÊÇÕâÆªÂÛÎĵĹ²Í¬Í¨Ñ¶×÷Õß¡£

ϸ°ûÇ¨ÒÆÊÇÒ»¸ö¸´ÔÓ¾«ÃܵĹý³Ì£¬°üÀ¨Æ¬×´Î±×ãµÄÉì³ö¡¢Õ³×ŰߵÄÐγÉ¡¢Î²²¿Õ³×ŰߵĽâ¾Û£¬µ÷¿Ø»ò¸Ä±äÇ¨ÒÆ¹ý³ÌÖеÄÈÎÒ»»·½Ú¶Ôϸ°ûµÄÇ¨ÒÆ»áÔì³ÉºÜ´óµÄÓ°Ïì¡£ÁíÍ⣬ϸ°ûÇ¨ÒÆÊ×ÏÈÒªÓëϸ°ûÍâ»ùÖʽӴ¥£¬¶øÕ³×ŰßÊÇϸ°ûÓëÖÜΧ»·¾³µÄ½Ó´¥µã£¬Æä×é×°ºÍ½â¾Û¼´Õ³×ŰߵÄÖÜת£¨Turnover of focal adhesion£©Ó°Ïìϸ°ûµÄÐÎ×´¡¢Î±×ãÐγɵIJ¿Î»ºÍ·½Ïò£¬×îÖÕϸ°ûÍâºÍϸ°ûÄÚµÄÐźÅЭͬ×÷ÓôÓʱ¼äºÍ¿Õ¼äÉϵ÷½ÚÕ³×ŰߵÄÐγÉ¡¢·Ö²¼ºÍÖÜתµÈ´Ó¶øÓ°Ïìϸ°ûµÄÇ¨ÒÆ¡£

Á˽âQIAGEN¸ü¶àµÄÎĿ⹹½¨¹¤¾ß

Õ³×ŰßÖÜתÊÇϸ°ûÇ¨ÒÆµ÷¿ØµÄ¹Ø¼ü»·½Ú£¬Ñо¿Ö¤ÊµÔÚϸ°ûÒÆ¶¯µÄ¹ý³ÌÖв¸È鶯Îïspectraplakinµ°°×µ÷¿ØÕ³×Ű߶¯Ì¬Ð­µ÷ÁËϸ°û¹Ç¼Ü¶¯Á¦Ñ§¡£ÔÚ¶àϸ°ûÉúÎïÖнø»¯±£ÊØ£¬ÖîÈçACF7Ò»ÀàµÄspectraplakinµ°°×¿ÉÒÔ½»ÁªÎ¢¹ÜºÍF-¼¡¶¯µ°°×(F-actin)¡£¾¡¹ÜÔ½À´Ô½¶àµÄÑо¿±íÃ÷£¬ACF7ÔÚЭµ÷ϸ°û¹Ç¼Ü¶¯Á¦Ñ§ÖÐÆðÖØÒª×÷Ó㬵«Ä¿Ç°ÈÔ²»ÊǺÜÇå³þACF7µÄʱ¿Õµ÷¿Ø»úÖÆ¡£

ΪÁË̽¾¿Ç±ÔڵĻúÖÆ£¬ÔÚÕâÆªÎÄÕÂÖÐÑо¿ÈËÔ±½âÎöÁËACF7µÄ NT£¨°±»ùÄ©¶Ë£©½á¹¹ÓòµÄ¾§Ìå½á¹¹£¬ÕâÒ»½á¹¹Óò½éµ¼ÁËF-actin»¥×÷¡£½á¹¹·ÖÎö½á¹û´Ùʹ¼ø±ð³öÁËACF7 CH½á¹¹ÓòÖеÄÒ»¸ö¹Ø¼üÀÒ°±Ëá²Ð»ù£¬Src/FAK¸´ºÏÎï½éµ¼ÕâÒ»ÀÒ°±Ëá²Ð»ùÁ×Ëữ¶ÔÓÚACF7½áºÏF-actinÖÁ¹ØÖØÒª¡£ÀûÓÃÆ¤·ô±íƤ×÷ΪģÐÍϵͳ£¬ËûÃǽøÒ»²½Ö¤ÊµACFÁ×ËữÔÚÕ³×Ű߶¯Ì¬ºÍÌåÄÚÍâ±íÆ¤Ç¨ÒÆÖÐÆð×Ų»¿É»òȱµÄ×÷Óá£

ÕâЩÑо¿½á¹û²ûÃ÷ÁËÔÚ¶¨Ïòϸ°ûÒÆ¶¯¹ý³ÌÖе÷¿ØÏ¸°ûÕ³¸½ºÍϸ°û¹Ç¼ÜЭµ÷µÄÒ»¸öÖØÒª·Ö×Ó»úÖÆ¡£

ϸ°ûÔ˶¯ÊÇËùÓÐÉúÃü²»¿É»òȱµÄÄÜÁ¦¡£ÔÚÈËÀàÖУ¬Ï¸°ûÔ˶¯¶ÔÓÚÅßÌ¥·¢Óý¡¢Ñ×Ö¢¡¢ÃâÒßÓ¦´ð¡¢´´ÉËÐÞ¸´µÈ¹ý³ÌÖÁ¹ØÖØÒª¡£¿ÆÑ§¼ÒÃÇ·¢ÏÖ£¬ÔÚϸ°û±íÃæµÄÕ³¸½·Ö×ÓÉÏ´æÔÚÒ»¸ö½ø»¯±£ÊصķÖ×ÓÃÜÂ룬Õâ¸ö¹ÅÀÏ·Ö×ÓÃÜÂëÊÇϸ°ûÔ˶¯ºÍÇ¨ÒÆµÄ¹Ø¼üµ÷¿ØÕß¡£ÕâÏîÑо¿·¢±íÔÚ2016Äê1ÔµÄNature Structural and Molecular BiologyÔÓÖ¾ÉÏ£¨Nature×Ó¿¯ÆÆÒëϸ°ûÇ¨ÒÆÃÜÂë £©¡£

Ñ©ÇÁÈ®ºÍϸ°ûÍÅÓÐʲô¹²Í¬Ö®´¦£¿¼ÓÖÝ´óѧʥËþ°Å°ÅÀ­·ÖУµÄÒ»ÏîÑо¿±íÃ÷£¬ËüÃǶ¼ÒÔȺÌåµÄ·½Ê½»î¶¯£¬ÐèÒªÒ»ÃûÁìµ¼ÕßÀ´È·±£ËüÃǶ¼ÑØ×ÅÏàͬµÄ·½ÏòÐнø¡£·Ö×Óϸ°ûºÍ·¢ÓýÉúÎïѧϵ½ÌÊÚDenise J. MontellºÍͬÊÂÃÇ£¬Õë¶ÔÒ»ÖÖ´æÔÚÓÚÈ«ÉíÉÏÆ¤Ï¸°ûÖеĵ°°×E-cadherinÕ¹¿ªÁËÈýÏî¶ÀÁ¢µÄÑо¿¡£Ñо¿ÈËÔ±ÀûÓùûÓ¬Âѳ²½ÒʾÁËE-cadherinÔÚ¼¯Ìåϸ°ûÇ¨ÒÆÖÐËùÆðµÄ×÷Óá£ËûÃǵÄÑо¿½á¹û±¨¸æÔÚ2014Äê5ÔÂ22ÈÕµÄCellÔÓÖ¾ÉÏ£¨CellÌôÕ½¿ÆÑ§½ÌÌõ£¬½Òʾϸ°ûÇ¨ÒÆÐ»úÖÆ £©¡£

ϸ°ûµÄÔ˶¯ÊÇÉúÃüµÄ»ù´¡£¬ËùÓÐϸ°û¶¼¾ßÓÐÕâÑùµÄÄÜÁ¦¡£±öϦ·¨ÄáÑÇ´óѧµÄÉúÀíѧ½ÌÊÚRoberto DominguezÑо¿ÍŶӺÍDavid Kast²©Ê¿ÔÚNature Structural & Molecular BiologyÔÓÖ¾ÉÏ·¢±íÎÄÕÂÖ¸³ö£¬IRSp53ÊÇÒ»¸ö¿ØÖÆÏ¸°ûÇ¨ÒÆÄÜÁ¦µÄ¹Ø¼üµ°°×¡£ËûÃÇÔÚϸ°û¾²Ö¹ºÍ»î¶¯×´Ì¬Ï½âÎöÁËIRSp53µÄµ÷¿Ø»úÖÆ£¬²¢²ûÊöÁËÕâÒ»¹ý³Ì¶Ô°©Ï¸°û×ªÒÆÄÜÁ¦µÄÓ°Ï죨Nature×Ó¿¯£ºÏ¸°ûÇ¨ÒÆµÄºËÐĵ°°× £©¡£

£¨ÉúÎïͨ£ººÎæÍ£©

ÉúÎïÍ¨ÍÆ¼öÔ­ÎÄÕªÒª£º

In vivo epidermal migration requires focal adhesion targeting of ACF7

Turnover of focal adhesions allows cell retraction, which is essential for cell migration. The mammalian spectraplakin protein, ACF7 (Actin-Crosslinking Factor 7), promotes focal adhesion dynamics by targeting of microtubule plus ends towards focal adhesions. However, it remains unclear how the activity of ACF7 is regulated spatiotemporally to achieve focal adhesion-specific guidance of microtubule¡­¡­

×÷Õß¼ò½é£º

Áººê

ÄУ¬1964Äê12ÔÂÉú£¬¹ãÎ÷±±Á÷ÈË£¬²©Ê¿£¬½ÌÊÚ£¬¼æÈÎÄÏ¿ª´óѧ¡¢ÄϾ©´óѧÎÞ»ú»¯Ñ§²©Ê¿Éúµ¼Ê¦ºÍÖÐÄÏ´óѧӦÓû¯Ñ§²©Ê¿Éúµ¼Ê¦¡£2012Äê7ÔÂÈÎÖй²¹ãÎ÷ʦ·¶´óѧµÚÊ®½ìίԱ»á³£Î¯£¬2002Äê1ÔÂÈιãÎ÷ʦ·¶´óѧУ³¤¡£¼æÈÎÒ©ÓÃ×ÊÔ´»¯Ñ§ÓëÒ©Îï·Ö×Ó¹¤³Ì¹ú¼ÒÖØµãʵÑéÊÒÅàÓý»ùµØ£¨½ÌÓý²¿ÖصãʵÑéÊÒ£©Ö÷ÈΡ£

Ñо¿ÁìÓò
Ö÷Òª´ÓÊÂѪÇå°×µ°°×µÄÉúÎïÎÞ»ú»¯Ñ§Ñо¿¡¢Ï¡ÍÁºÍ¹ý¶É½ðÊôÅäºÏÎïµÄºÏ³É¡¢½á¹¹ÒÔ¼°ÐÔÄÜÑо¿ºÍÖÐÒ©»îÐԳɷֵÄÎÞ»úÒ©ÎﻯѧÑо¿µÈ¹¤×÷¡£

Ñî·å½ÌÊÚ

±ÏÒµÓÚÖйú¿ÆÑ§Ôº¸£½¨ÎïÖʽṹÑо¿Ëù£¬ÏÖÈιãÎ÷ʦ·¶´óѧÑо¿ÉúѧԺ¸±Ôº³¤,»ñµÃ12½ì¹ãÎ÷ÇàÄê¿Æ¼¼½±¡£2006-2010ÄêÔÚÃÀ¹úÄÜÔ´²¿-²¼Â³¿Ëº£ÎĹú¼ÒʵÑéÊÒ´Óʲ©Ê¿ºóÆÚ¼ä£¬²ÎÓë2ÏîÃÀ¹ú¹úÁ¢ÎÀÉúÔº£¨NIH£©ÖØ´ó¿ÎÌâºÍ1ÏîÃÀ¹úÄÜÔ´²¿ÖØ´ó¿ÎÌâ¡£Ö÷Òª³É¹û·¢±íÔÚ¹ú¼ÊÖªÃûҩѧºÍÉúÎïÆÚ¿¯(Mol pharm£¬Eur J pharm Biopharm, J Mol Bio)µÈ£¬±»Nature, Science, Nature×Ó¿¯ºÍpNASµÈÆÚ¿¯ÒýÓá£ÊÜÑûÔÚ¹úÄÚÍâÖªÃû¿¯Îï׫д¶àƪ×ÛÊö;ÔÚFuture Med ChemºÍ Curr pharm DesignÆÚ¿¯×«Ð´×¨ÌâÆÀÂÛ; µ£ÈÎÃÀ¹ú»¯Ñ§»á¡¢ElsevierºÍWileyµÈSCI¹ú¼Ê¿¯ÎïÉó¸åר¼Ò,¡¶Curr pharm Design¡·¿Í×ùÖ÷±à.

Ñо¿ÁìÓò
ÐÂÐÍÒ©ÎïºÍÔØÒ©ÌåϵµÄÑо¿£º1)Óë¼²²¡Ïà¹Øµ°°×ÖʵĽṹºÍ¹¦ÄÜ2)»ùÓÚµ°°×ÖÊÉè¼Æ¿¹Ö×ÁöÒ©ÎïºÍÔØÒ©Ìåϵ3)Ò©ÎïÍâÅűõĻúÖÆ¼°ÆäÒÖÖÆ¼ÁµÄÉè¼Æ.